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injury in normolipemic swine. Formalin fixed, paraffin embedded coronary
artery sections were stained using conventional ABC methodology and im-
munoperoxidaae techniques. Human melanoma and normal kidney aerved
as positive controls. Deletion and substitution controls for primary antibody
were negative. Staining of contiguous sections with specific cell marker anti-
bodies identified SMC, EC, macrophages (MAC) and myofibroblasts (MYF).
UW%staining was ordinally graded from O (none) to 3 (strong). Resuk In
the uninjured coronav artery, only the Iuminal endothelium expressed a,&+
Marked temporal-spatial variation in a.h expression was noted in all vessel
wall locations, colocalizing with platelet thrombus (?24 hours), MF,SMC, EC
and to a lesser degree MAC (see Table).
Location 7 days 14 days 20 daya 3 months
Neoinlima (EC, WC) 2 3 2 1
Media (SMC) 3 2 1 0
Adventitia(W ME MAC) 3 2 2 1
Conckisions: Following deep arterial injury, temporal av,83upregulation
by SMC, EC, and MF peaks at 7 daya in the media and adventitia, and
at 14 days within the neointima. Following injury, a,fk is also upregulated
within the Iuminal EC and the medial SMC of the vasa vasora (VW. Temporal
avp3 uPre9ulation OfferSa mechanism for SMC, EC, and MF recruitment into
regions of restenotic hyperplaaia. Sustained u.i% integrin blockade may thus
offer a cogent atrategy to limit reatenosia.
[960-111] M~dulatiwIof Platelet Ne”t~ophill~te~a~i~n~ith
Pharmacological Inhibition of Fibrinogen Binding
to Pletalet GPllb/flla Raceptor
Z. Xiao, P.Theroux, Y. Lu, M. Ghiteacu, M.M. Frojmovic. Montreal Heart
krstitute, Montreal, Quebec, Canada
This study was designed to investigate whether the inhibition of fibrinogen
binding to the platelet membrane receptor GPllblllla (PL-Fb) could interfere
with neutrophil-platelet adhesion (PL-Ne). Citrated whole blood obtainad from
30 pts with unstable angina before and 4 to 12 hours after tirofiban (Tir,O.1-
0.15 @kg/rein) was studied uaing 3 color wholeblood flowcyfometry. The
leukocyte population was defined with a nucleic acid dye (LDS-751) and a
monoclinal antibody (MAb), anti-CD45-PE, and the neutrophil subpopulation
gated with cell size and granularity. PL-Ne waa quantified with MAb anti-
CD42a-FITC, as mean FITC intensify per neutrophil (PL-FI). FITC-labeled
fibrinogen wee used to detect platelet-fibrinogen binding, as % FITC-positive
platelets (%PL-Fb). TRAP 5 #M, ADP 5 wM, and ADP plus epinephrine 1
PM (ADP + E) were used aa agonists. Tir did not prevent platelet P-aelectin
expression, but decreased the number of platelets bound per neutrophil in
basal atate and following agonists stimulation (Table, x + SD, *p <0.05, ‘p
<0.01 vs pre-Tir). The decrease significantly correlated with the inhibition of
fibrinogen binding to plateleta (r = 0.75).
Pra-_nr Tr
PL-FI % PL-FII PL-FI ?/.PL-Fb
easel 3.0k 1,4 3.4*2.5 2.2 +0.5” 0.6 * 0.4$
ADP 5.5 * 1.4 86.7+ 9.2 3.1 + 0.6# 9.0+8.1#
TRAP 10.3+ 2.4 88.5* 4.8 6.4 * 2.0# 40.8*30#
ADP + E 7,0 l2,8 94.5*3.O 3.4 * o.9# 22.3* 21#
GPllb/llla blockade reduces plateletmeutrophil binding; thia may prevent
mesa accumulation of platelet antUor leukocyte on injured endothelium.
m960112 Intranesal Antiplatelet/Antithrombotic Efficacy of
the Platelat GPllb/llta Antsgoniat, DMP754
S.A. Mouaa, D.-X. Mu, M. Hussain. The Du Pent Merck Pharmaceutical
Company, Wilmington, DE, USA
DMP754 after ita conversion to the free acid form, XV459 is a potent
and specific platelet GPllblllla receptor antegoniat. The present study was
undetlaken to determine its intrenaeal vereua intravenous and oral an-
tiplatelef/antithrombotic efficacy in dogs. Either DMP754 or its free acid
form, XP280 demonstrated maximal and com@rable antiplatelet efficacy at
0.025-0.1 m~kg, IVorintranasel in mongrel doga.Theantiplatelet efficacyof
DMP754 at 0.1 mr#kg, intrqnasal orlVwasdetermined in across-over deai9n
(n= 8 in each group). In this study, a comparable and maximal antiplatelet
efficacy for DMP754 after intranaaal or IV was demonstrated with 97 A 6S%
intreneeal bioavailability. DMP7&t administered at 0.1 mg/kg, intranasally
or IV and at 0.3 mglkg, PO prevented the incidence of electrolytic injury-
induced arterial thrombosis in the carotid artery and prevented the incidence
of cyclic flow reduction (CFR) in mechanically injured and stenosed femoral
artery. Additionally, DMP754 at the above doae regimena resulted in aignifi-
cent reduction of electrolytic injury-induced’ femoral vein thrombosis. Theae
data indicate that DMP754 has a comparable intranaeal and intravenous an-
tiplatelet and antithrombotic profile along with a significant improvement over
its oral antiplateletiantithrombotic profile. These data suggest the potential
utility of intranasal DMP754 in various acute and chronic thromboembolic
disorders.
1960-113] Moaain:ACellMembrane Protein Regulating
Rsceptor-Cytoskelaton Interaction in Human
Platelets
K.M. Hoffmeister, B. Kraus, A. Gamulescu, J. vom Dahl, D.-C. Fischer,
P.Hanrath. UniveraifyofAachen Hoepita/, Aachen, Germany
Following various stimuli, platelet activation goes along with rapid ahape
change from a discoid biconcave form to a phenotype with multiple protru-
sion. This shape change and the reorganisation of the cytoskeleton favors
cell-ceil and cell-matrix interactions. Moesin, a 78 kDa protein, is a member
of the ezrin, radixin and moesin (ERM) protein family and there is evidence
that they interact with both cytoskeletel and membrane component. Ina pre-
vioua study, moesin was purified to homogeneityfrom human platelet Iyeate
and apecific antibodies were elicited in chicken.
To study moesin-cytoskeleton interactions the cytoskeleton of resting
and activated platelets was isolated by triton X 100 Iysis and centrifugatlon
resulting in a pellet fraction containing cytoskeletal proteins (15,000 x g:
actin based cytoskeleton; 100,000 x g: membrane cytoskeleton) and a
supernatant consisting of soluble not cytoskeletal bound proteins. Western
blot analysis with a moesin specific antibody demonstrated the preaence of
moeein in the 15,1110x g pellet fraction only in thrombin activated platelets.
In contrast, in the 100,000 x g pellet fraction moesin was found in resting
and activated platelets with the majority of this protein remaining in the
aoluble fraction. This finding implies, that an association of moesin with the
filamentous actin occurs, while most of the protein is associated with the
membrane cytoskeleton or soluble during activation of platelets.
For further analysia of moesin interaction, platelet plasma membranes
were isolated by glycerol Iysis and an sucrose step gradient at 63,000 x
g. Immunoblotting of the plasma membrane fraction revealed the presence
of moesin despite aome bands of slower motility then moeain. lmmuno-
precipitation with polyclonal moesin antibody of platelet plasma membrane
fraction and whole RIPA buffer Iysed platelets showed the presence of at
least 3 potential binding proteins. These data indicate that moesin functiona
as a transmitter between the cytoskeleton and membrane components in
platelets.
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-[ TheParicardiumaaaRepositOwforan
AngiogenicGrowthFactor: Effact of
Intrapericardial Baaic Fibroblast Growth Factor on
Myocardial Collateral Development
M. Shou, D.F. Lazarous, J.A. Stiber, V. Thirumurti, E. Hedge, E.F. Unger.
NHLBI, Bethesda, MD, USA
We have previously shown that basic fibroblast growth factor (bFGF) en-
hancea myocardial collateral development in dogs when administered via a
systemicarterial or intracoronaty (IC) route. In thia study,we asseasedthe ef-
ficecyof repeated intrapericerdial (1P)bFGFdelivery, with collateral perfuaion
aa the primary endpoint. We hypothesized that the pericardium could act se
a local repository for bFGF,expoaing epicardial collateral to a relatively high
bFGF concentration. Such a route of delivery might decrease the minimum
effective bFGF dose, and obviate the need for repeated IC injections. Fifteen
dogs underwent placement of ameroid constrictor on the left circumflex
coronary artety (LCX)and implantation of indwelling 1Pcatheters. Dogs were
randomized to receive bFGF 2 mgfd x 7 daya or vehicle during the period
10-16 daya after bmeroid placement, an optimum treatment interval baaed
on our previous studies using other routea of bFGF delivery. Radiolabeled
microsphere were used to assess collateral perfusion in the conscioue state
during maximal corona~ vasodilatation 36 days after ameroid placement.
Maximal LCXterritory perfusion was 2.02 & 0.24 ml/min/g in bFGF-treated
doga and 1.94 + 0.18 ml/min/g in controls, with LCx/normal zone perfusion
ratios of 0.39 + 0.03 and 0.37 t 0.03, respectively, (P = NS). Thua, in
